Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

New Items

Tykerb Lapatinib Tablet

Tykerb Lapatinib Tablet
  • Tykerb Lapatinib Tablet
  • Tykerb Lapatinib Tablet
Get Best Quote
Approx. Price: Rs 2,000 / PacketGet Latest Price

Product Details:

Packaging Size250MG 30TAB
BrandTykerb
CompositionLapatinib
ManufacturerNovartis
Treatmentbreast cancer patients already using capecitabine (Xeloda)
FormTablet
Therapeutic Usesbreast cancer patients already using capecitabine (Xeloda)
Side Effectdiarrhea,fatigue,nausea and rashes.lapatinib related rash is associated with improved outcome
Strength250mg 30tab bottle

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours.It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

Status
On March 13, 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda). In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated (in combination with letrozole).

On August 2, 2013, India''s Intellectual Property Appellate Board revoked the patent for Glaxo''s Tykerb citing its derivative status, while upholding at the same time the original patent granted for lapatinib.

Mode of action
Lapatinib inhibits the tyrosine kinase activity associated with two oncogenes, EGFR (epidermal growth factor receptor) and HER2/neu (human EGFR type 2). Over expression of HER2/neu can be responsible for certain types of high-risk breast cancers in women.

Like sorafenib, lapatinib is a protein kinase inhibitor shown to decrease tumor-causing breast cancer stem cells.

Lapatinib inhibits receptor signal processes by binding to the ATP-binding pocket of the EGFR/HER2 protein kinase domain, preventing self-phosphorylation and subsequent activation of the signal mechanism (see Receptor tyrosine kinase#Signal transduction).

Clinical application
Breast cancer -Lapatinib is used as a treatment for women''s breast cancer in treatment-naive, ER+/EGFR+/HER2+ breast cancer patients and in patients who have HER2-positive advanced breast cancer that has progressed after previous treatment with other chemotherapeutic agents, such as anthracycline, taxane-derived drugs, or trastuzumab (Herceptin).

A 2006 GSK-supported randomized clinical trial on female breast cancer previously being treated with those agents (anthracycline, a taxane and trastuzumab) demonstrated that administrating lapatinib in combination with capecitabine delayed the time of further cancer growth compared to regimens that use capecitabine alone. The study also reported that risk of disease progression was reduced by 51%, and that the combination therapy was not associated with increases in toxic side effects.The outcome of this study resulted in a somewhat complex and rather specific initial indication for lapatinib-use only in combination with capecitabine for HER2-positive breast cancer in women whose cancer have progressed following previous chemotherapy with anthracycline, taxanes and trastuzumab.

Early clinical trials have been performed suggesting that high dose intermittent lapatinib might have better efficacy with manageable toxicities in the treatment of HER2-overexpressing breast cancers.

Adverse effects
Like many small molecule tyrosine kinase inhibitors, lapatinib is regarded as well tolerated. The most common side effects reported are diarrhea, fatigue, nausea and rashes.lapatinib related rash is associated with improved outcome.In clinical studies elevated liver enzymes have been reported. QT prolongation has been observed with the use of lapatinib ditosylate but there are no reports of torsades de pointes. Caution is advised in patients with hypokalaemia, hypomagnesaemia, congenital long QT syndrome, or with coadministration of medicines known to cause QT prolongation. In combination with capecitabine, reversible decreased left ventricular function are common (2%).
Request
Callback


Additional Information:

  • Packaging Details: 250mg 30tab bottle
Yes! I am Interested

Bevacizumab Bevicra 400, 100 Mg Injection Glenmark

Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
  • Bevacizumab Bevicra 400, 100 Mg Injection Glenmark
Get Best Quote
Approx. Price: Rs 100 / PieceGet Latest Price

Product Details:

Packaging Size400 Mg,100 Mg Injection
BrandBevicra
CompositionBevacizumab
ManufacturerGlenmark
Packaging400 Mg,100 Mg Vial
TreatmentCancer It Is Given By Slow Injection Into a Vein And Used For Colon Cancer,Lung Cancer,Glioblastom
Dosage Form400 Mg,100 Mg
Therapeutic UsesCancer It Is Given By Slow Injection Into a Vein And Used For Colon Cancer,Lung Cancer,Glioblastom
InteractionsBevacizumab Inhibits The Growth Of Blood Vessels,Which is part of the body's normal healing and mai
Side EffectDifficulty Breathing,Flushing,Severe Dizziness,Nausea/Vomiting,Shaking,Or Chest Pain.

Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age related macular degeneration it is given by injection into the eye.

Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash.Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection.When used for eye disease side effects can include vision loss and retinal detachment.Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF A), in other words anti VEGF therapy.

Bevacizumab was approved for medical use in the United States in 2004.It is on the World Health Organizations List of Essential Medicines, the safest and most effective medicines needed in a health system.It is listed for its use in treating eye disease.
Contents

Medical uses

Colorectal cancer
Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer when used with standard chemotherapy treatment (as first-line treatment) and with 5-fluorouracil based therapy for second line metastatic colorectal cancer.[citation needed]
It was approved by the European Medicines Agency (EMA) in January 2005, for use in colorectal cancer.
Also can be used some cases Lung cancer,Breast cancer,Renal cancers,Brain cancers,Eye disease,Ovarian cancer.

Administration
Bevacizumab is usually given intravenously every 14 days. In colon cancer, it is given in combination with the chemotherapy drug 5 FU (5 fluorouracil), leucovorin, and oxaliplatin or irinotecan.[medical citation needed] For treatment of eye diseases it is injected intravitreously.

Adverse effects

Bevacizumab inhibits the growth of blood vessels, which is part of the bodys normal healing and maintenance. The body grows new blood vessels in wound healing, and as collateral circulation around blocked or atherosclerotic blood vessels.

The main side effects are hypertension and heightened risk of bleeding. Bowel perforation,Fatigue and infection are also common. In advanced lung cancer, less than half of patients qualify for treatment.Nasal septum perforation and renal thrombotic microangiopathy

Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF A). VEGF A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer.

Approval
It received its first approval, for combination use with standard chemotherapy for metastatic colon cancer.It approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain.

The drug remains approved for breast cancer use in other countries including Australia.
The European Commission approved bevacizumab in combination with paclitaxel for the first line treatment of metastatic breast cancer.
In 2008, the FDA approved bevacizumab for use in breast cancer. 
In 2011, the US Food and Drug Administration removed bevacizumab indication for metastatic breast cancer after concluding that the drug has not been shown to be safe and effective. The specific indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with paclitaxel for the treatment of people who have not received chemotherapy for metastatic HER2-negative breast cancer.
Request
Callback


Additional Information:

  • Packaging Details: 400mg , 100mg vial
Yes! I am Interested

Sorafenat Tablet

Sorafenat Tablet
  • Sorafenat Tablet
Get Best Quote
Approx. Price: Rs 10 / PackGet Latest Price

Product Details:

UsageClinical, Hospital
Packaging Size120 Tablets
Drug NameSorafenib

Request
Callback
Yes! I am Interested

Abraxane Nab-Paclitaxel Injection

Abraxane Nab-Paclitaxel Injection
  • Abraxane Nab-Paclitaxel Injection
  • Abraxane Nab-Paclitaxel Injection
  • Abraxane Nab-Paclitaxel Injection
Get Best Quote
Approx. Price: Rs 10 / PieceGet Latest Price

Product Details:

ManufacturerCipla,Cadila,Hetro
BrandCipla
Dose Strength100mg
CategoryBreast Cancer
Compositionnanoparticle albumin-bound paclitaxel
Drugnanoparticle albumin-bound paclitaxel
Generic NameNab paclitaxel
Dose100 mg
Drug NamePaclitaxel
Injectable FormSolution

Protein-bound paclitaxel, also known as nanoparticle albumin bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".

This treatment was approved in the United States in 2005, and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed. In 2012, the FDA widened the approved uses to include treatment for NSCLC. In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.

What is the difference between paclitaxel and nab paclitaxel?Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial
Request
Callback


Additional Information:

  • Packaging Details: 100mg
Yes! I am Interested

Revolade Eltrombopag Tablet

Revolade Eltrombopag Tablet
  • Revolade Eltrombopag Tablet
Get Best Quote
Approx. Price: Rs 1,600 / PieceGet Latest Price

Product Details:

Dose/Strength (ex. 1 mg or 1ml)25 mg
Packaging Size4 x 7 Tablets
UsageHospital
Drug NameEltrombopag

Request
Callback
Yes! I am Interested

Cramaffin - Cremacorn Oral Suspension

Cramaffin - Cremacorn Oral Suspension
  • Cramaffin - Cremacorn Oral Suspension
Get Best Quote
Approx. Price: Rs 10 / BottleGet Latest Price

Product Details:

Minimum Order Quantity100 Bottle
Pack Sizebottle syrup
Pack Type170ml
BrandCramacorn

Request
Callback
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS